EMA Authorised: Privigen (human normal immunoglobulin (IVIg)) — CSL Behring GmbH

View source ↗

Summary

Authorised status for Privigen (human normal immunoglobulin IVIg) by CSL Behring GmbH in the EMA; therapeutic areas include various immunologic and neurologic c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Marrow Transplantation
• Guillain-barre Syndrome
• Immunologic Deficiency Syndromes
• Mucocutaneous Lymph Node Syndrome
• Purpura Thrombocytopenic Idiopathic

Drugs mentioned

• Privigen (intravenous immunoglobulin (IVIG))

Snippet

Status: Authorised. Therapeutic area: Purpura, Thrombocytopenic, Idiopathic;Bone Marrow Transplantation;Immunologic Deficiency Syndromes;Guillain-Barre Syndrome;Mucocutaneous Lymph Node Syndrome. MAH: CSL Behring GmbH. Decision date: 26/05/2026